The Flow Cytometry Core Core is a fee-for-service facility providing flow cytometry instrumentation and expertise to members of the University of Michigan Comprehensive Cancer Center (UM-CCC). The Flow Core has been in continuous operation since 1964 with the main facility residing in dedicated laboratory space provided by the Comprehensive Cancer Center since 1997, For calendar year 2010 there were 95 UM-CCC-affiliated members using the facility, accounting for 51% of the core user base (187 total users) while accounting for 82% of total flow core usage. The Flow Core also provides access to all UM investigators in a broad range of basic and medical sciences. Investigators deliver pre-processed samples to the Core for flow cytometric analysis and/or cell sorting. The core operates on a fee-for-service basis, with a recharge rate of $120/hour. Comprehensive Cancer Center Investigators are able to bill 50% of their usage directly to the CCC core support grant. Recharge rates are further discounted for those investigators willing to provide self-operation on unstaffed Instrumentation. Instruments are operated by trained flow cytometry operators (7.6 FTEs). Access to the facility Is reserved in advance (24-hour minimum) on a first-come basis. Core instrumentation includes one Coulter MoFlo XDP multilaser high-speed ceil sorter, three BD Biosciences FACSAria multilaser high-speed cell sorters, two BD Biosciences FACSDIVa multilaser high-speed cell sorters, a Coulter Cyan multilaser analzer, two BDBiosciences FACSCanto II analyzers, two BD Biosciences FACSCalibur multilaser analyzers, and a Coulter Z2 Particle Counter.

Public Health Relevance

The study of human clinical disease necessitates the ability to Identify and isolate discrete populations of human cells. The University of Michigan Flow Cytometry Core Facility provides a broad range of Instrumentation and expertise to researchers in the University of Michigan Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-25
Application #
8559883
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
25
Fiscal Year
2013
Total Cost
$122,354
Indirect Cost
$53,077
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865
Eberl, Markus; Mangelberger, Doris; Swanson, Jacob B et al. (2018) Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. Cancer Cell 33:229-243.e4
Lazarus, Jenny; Maj, Tomasz; Smith, J Joshua et al. (2018) Spatial and phenotypic immune profiling of metastatic colon cancer. JCI Insight 3:
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131:

Showing the most recent 10 out of 1493 publications